Method for Treating or Preventing Prostatic Conditions
Project Leaders: Cal Meyers, Todd Winters, William Banz, Yuqing Hou
Unit: College of Science, Dept. of Chemistry and Biochemistry
Brief Description:
This invention relates to the use of estrogenic carboxylic acids in improved therapies for the treatment of a variety of estrogen-related and other endocrine-related symptoms and disease conditions in mammals. Previously, the metabolic effects of these enantiomers were unknown. However, rat studies have resulted in significant prostate shrinkage without feminization. Comparisons tests to finasteride have been conducted with favorable results. Cell line studies, including prostate cancer cell lines, have shown improved cancer cell growth inhibition compared to other therapeutic compounds. An inexpensive synthesis for these compounds has also been developed.
Patent Status:
U.S. Patent No. 6,608,111, issued August 19, 2003. Additional patents pending.
Potential Commercial Uses:
This invention may have therapeutic applications in the treatment of prostate cancer and benign prostate hypertrophy. Additionally, the research indicates that there may be applications in the treatment of endocrine-related cancers, especially prostate cancer (as well as cancer of the breast, uterus, and cervix), peri- and post-menopausal symptoms, regulation of follicular development and ovulation, oral contraception, obesity, cardiovascular disease and promotion of cardiovascular health, Alzheimer's disease, osteoporosis, pattern baldness, and other estrogen-related disorders. This invention may also have potential uses as a specific estrogen receptor modulator (SERM).
Contact:
Jeff Myers, Senior Technology Transfer Specialist, (618) 453-4543, fax: (618) 453-8038